Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Oct 1.

Published in final edited form as: J Immunother. 2018 Oct;41(8):361–368. doi: 10.1097/CJI.0000000000000242

Fig. 3 — CSC-DC vaccination combined with immune checkpoints blockade changed the phenotype of CD8⁺ T cells. A, B, C: The percentage of CD8⁺ T cells (A), PD-1⁺CD8⁺ T cells (B) and CTLA-4⁺CD8⁺ T cells (C) in the spleens harvested from mice treated with PBS, H-DC vaccines, CSC-DC vaccines alone or in combination with anti-CTLA-4 and/or anti-PD-L1 as indicated. Each column represents the mean±SE of three independent experiments performed. D, E: FACS plots representing PD-1⁺CD8⁺ T cell (D) and CTLA-4⁺CD8⁺ T (E) populations in the spleens of mice treated as indicated. Single-cell suspensions were prepared from spleens on day 30 after tumor challenge and stained for immune checkpoints, PD-1 and CTLA-4.

Fig. 3 — CSC-DC vaccination combined with immune checkpoints blockade changed the phenotype of CD8⁺ T cells. A, B, C: The percentage of CD8⁺ T cells (A), PD-1⁺CD8⁺ T cells (B) and CTLA-4⁺CD8⁺ T cells (C) in the spleens harvested from mice treated with PBS, H-DC vaccines, CSC-DC vaccines alone or in combination with anti-CTLA-4 and/or anti-PD-L1 as indicated. Each column represents the mean±SE of three independent experiments performed. D, E: FACS plots representing PD-1⁺CD8⁺ T cell (D) and CTLA-4⁺CD8⁺ T (E) populations in the spleens of mice treated as indicated. Single-cell suspensions were prepared from spleens on day 30 after tumor challenge and stained for immune checkpoints, PD-1 and CTLA-4.